Overview of the Annual General Meeting
Company announcement – No. 7 / 2025
Resolutions from Zealand Pharma's Annual General Meeting 2025
Copenhagen, Denmark - Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) is a biotechnology firm dedicated to developing innovative peptide-based medicines. The company's Annual General Meeting of 2025 took place as a hybrid meeting, integrating electronic and physical attendance.
Key Resolutions Approved
During the meeting, all proposals presented received the approval of shareholders.
Annual Financial Report
The management reported on Zealand Pharma's activities in the previous financial year. The audited Annual Report for 2024 was also approved. Notably, the financial results for 2024 reflected a loss of TDKK 1,078,828, which will be carried forward into the next year.
Board of Directors Elections
All current shareholder-elected members were re-elected to Zealand's Board of Directors based on the Nomination Committee's recommendations:
- Alf Gunnar Martin Nicklasson
- Kirsten Aarup Drejer
- Jeffrey Berkowitz
- Leonard Kruimer
- Bernadette Mary Connaughton
- Elaine Sullivan
- Enrique Conterno
After the meeting, the Board of Directors elected Martin Nicklasson and Kirsten Aarup Drejer as Chair and Vice-Chair, respectively.
The Audit Committee includes Martin Nicklasson, Bernadette Mary Connaughton, and Jeffrey Berkowitz, while Leonard Kruimer serves as the chair.
The Remuneration Committee features Enrique Conterno Martinelli and Leonard Kruimer, with Martin Nicklasson presiding. The Scientific Committee comprises Elaine Sullivan and Enrique Conterno Martinelli, chaired by Kirsten Aarup Drejer. Lastly, Leonard Kruimer and Martin Nicklasson lead the Nomination Committee.
Auditor and Financial Authorizations
Re-appointment of Auditor
Pwc was reaffirmed as Zealand Pharma's auditor, coinciding with the Audit Committee's recommendation.
Treasury Shares Acquisition
The Board was authorized to facilitate the acquisition of treasury shares up to 10% of the company's share capital until the next Annual General Meeting.
Remuneration Report Approval
The Annual General Meeting approved Zealand Pharma’s Remuneration Report, which provides insights into the company’s compensation practices.
Future Capital Increases
Share Capital and Pre-emption Rights
The Board received authorization to increase the share capital of Zealand Pharma by DKK 7,100,000 until 2030 without pre-emption rights for existing shareholders. Furthermore, they were authorized to undertake additional capital raises, including up to DKK 14,200,000 with pre-emption rights.
Warrant Issuance Authorization
The existing authorization for issuing warrants has been extended until 2030, increasing the number of available warrants to 2,573,740.
All new amendments to Zealand Pharma's Articles of Association will be published on the company’s website after being registered with the relevant authorities.
About Zealand Pharma
Founded in 1998 and headquartered in Copenhagen, Zealand Pharma A/S (Nasdaq: ZEAL) focuses on creating peptide-based medicines. The company has successfully advanced over ten drug candidates into clinical development, with two having reached the market and three others in late-stage trials. Zealand maintains various development and commercial partnerships to broaden the reach of its innovative products.
Contact Information
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Email: akrassowska@zealandpharma.com
Adam Lange
Investor Relations Officer
Email: alange@zealandpharma.com
Neshat Ahmadi
Investor Relations Manager
Email: neahmadi@zealandpharma.com
Frequently Asked Questions
What was the main outcome of Zealand Pharma's Annual General Meeting?
All proposals submitted were approved, including financial matters and board elections.
Who are the key members of the Board of Directors?
The key members include Martin Nicklasson as Chair and Kirsten Aarup Drejer as Vice-Chair.
What financial results were presented?
Zealand Pharma reported a loss of TDKK 1,078,828 for the fiscal year 2024.
What authorization was given regarding share capital?
The Board was authorized to increase the share capital without pre-emption rights for current shareholders up to DKK 7,100,000.
How many warrants can Zealand Pharma issue under the new authorization?
The new authorization permits the issuance of up to 2,573,740 warrants.
